SCHEMBL201712

SCHEMBL201712

CCOc1ccc(-c2ccccc2C(=O)N2CCS[C@H]2C(=O)NOCc2ccccc2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 3/20 0.41
LMNA P02545 2/20 0.41
HCRTR2 O43614 2/20 0.41
KDM4E B2RXH2 1/20 0.41
FFAR1 O14842 1/20 0.38
FFAR4 Q5NUL3 1/20 0.38
NPC1 O15118 3/20 0.38
RAB9A P51151 3/20 0.38
HSD17B10 Q99714 2/20 0.38
ALDH1A1 P00352 2/20 0.38
HPGD P15428 2/20 0.38
TP53 P04637 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
PKM P14618 1/20 0.37
MAPK1 P28482 1/20 0.37
KCNH2 Q12809 1/20 0.37
HRH3 Q9Y5N1 1/20 0.37
RECQL P46063 2/20 0.36
NR1D1 P20393 1/20 0.36
GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL201123 0.89 LMNA (0.37) HCRTR1LMNAHCRTR2
SCHEMBL203188 0.87 HCRTR1 (0.45) HCRTR1HCRTR2RECQL
SCHEMBL202498 0.85 MTTP (0.45) HCRTR1HCRTR2
SCHEMBL201557 0.83 HCRTR1 (0.41) HCRTR1HCRTR2NPC1RAB9AGHSR
SCHEMBL201387 0.77 SPHK2 (0.44) LMNAKDM4ENPC1RAB9AALDH1A1
SCHEMBL201386 0.77 SPHK2 (0.44) LMNAKDM4ENPC1RAB9AALDH1A1
SCHEMBL202603 0.76 NPC1 (0.44) NPC1RAB9ASMN1; SMN2
SCHEMBL200926 0.74 PPARG (0.38) HCRTR1LMNAHCRTR2MMP13
SCHEMBL200986 0.74 PPARG (0.38) HCRTR1LMNAHCRTR2MMP13
SCHEMBL201372 0.72 PPARG (0.42) LMNARECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088804-B2 N-hydroxyamide derivatives possessing antibacterial activity PFIZER INC. (US) 2012-01-03 US disclosed
EP-2338878-A2 N-hydroxyamide derivatives possessing antibacterial activity Vicuron Pharmaceuticals, Inc. (US) 2011-06-29 EP disclosed
US-20100022605-A1 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. 2010-01-28 US disclosed
EP-1963262-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY Vicuron Pharmaceuticals, Inc. (US) 2008-09-03 EP disclosed
WO-2007069020-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. (US) 2007-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022605-A1 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY NAAA, HDHD5, HACL2 HCRTR1 1201/4885LMNA 1020/4885HCRTR2 1892/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.